Hiroyasu Muramatsu

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Although mitogen-activated protein kinase kinase (MEK) is a key signaling molecule and a negative regulator of insulin action, it is still uncertain whether MEK can be a therapeutic target for amelioration of insulin resistance (IR) in type 2 diabetes (T2D) in vivo. To clarify whether MEK inhibition improves T2D, we examined the effect of continuous MEK(More)
  • 1